PHOENIX TECHNOLOGIES LLC

UEI CHEBZZQFKXF3

SAM Inactive

Total Awards

Since 2017

Total Won

Federal contracts

Avg Award

Largest Award

Last: 2017-07-28

Capabilities

Primary NAICS

611420

Contract Vehicles Held

Federal contract vehicles (GWACs, GSA Schedules, BPAs, IDCs, BOAs) where this vendor is the recipient. Task orders are issued through these vehicles.

Type	Agency	Amount	Expires	NAICS	Set-Aside
FSS / GSA Schedule	General Services Administration	-	2021-10-12	611420	Open / Full and Open

Sourced from USAspending via BidSparq's vehicle directory. Hard cap 25 results.

SEC public filings

Phoenix Education Partners, Inc. PXED· NYSE· Services-Educational Services

All filings on SEC.gov ↗

Recent filings

10-QQuarterly report
2026-07-14
8-KMaterial event
2026-07-14
8-KMaterial event
2026-07-13
10-QQuarterly report
2026-04-07
8-KMaterial event
2026-04-07
8-KMaterial event
2026-02-13
10-QQuarterly report
2026-01-13
8-KMaterial event
2026-01-13
DEF 14AProxy statement
2025-12-29

Source: SEC EDGAR ( sec.gov ). 10-K filings often disclose federal-revenue concentration, contract-specific risk factors, and segment performance: capture-grade intel public companies must publish.

NIH research funding

PHOENIX CHILDREN'S HOSPITAL · 5-year window

All NIH grants on reporter.nih.gov ↗

Awards (5y)

Total funded (5y)

$24.1M

Top NIH institute

National Institute of Neurological Disorders and Stroke

$12.0M · 10 grants

Top 5 projects by award amount

Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
5U01DA057862-03 · PI Frances Rudnick Levin · National Institute on Drug Abuse · FY2024
$3.6M
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
1U01DA057862-01 · PI Frances Rudnick Levin · National Institute on Drug Abuse · FY2022
$2.7M
Development and Validation of Therapy for Mucopolysaccharidosis III
5U44NS089061-05 · PI Tsui-Fen Chou · National Institute of Neurological Disorders and Stroke · FY2022
$2.4M
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
5U01DA057862-02 · PI Frances Rudnick Levin · National Institute on Drug Abuse · FY2023
$2.4M
Development of gene replacement therapy for Sanfilippo Syndrome Type C
1R44NS129393-01 · PI Srikanth Singamsetty · National Institute of Neurological Disorders and Stroke · FY2022
$1.5M

Funding mix by NIH institute

National Institute of Neurological Disorders and Stroke$12.0M · 10
National Institute on Drug Abuse$9.0M · 4
National Institute of Dental and Craniofacial Research$2.6M · 5
National Cancer Institute$382K · 1
National Institute on Minority Health and Health Disparities$125K · 1

Source: NIH RePORTER : federal biomedical research grants. Different revenue stream from procurement contracts; signals R&D / academic-medical capability.

Top customer agencies

Agencies that have awarded the most contracts to PHOENIX TECHNOLOGIES LLC

General Services Administration
1 • $0

Top NAICS by award volume

Where PHOENIX TECHNOLOGIES LLC has won the most contracts

611420
1 awards • $0

Set-aside profile

How PHOENIX TECHNOLOGIES LLC's wins break down by set-aside category

NONE

1 awards

100% of total

Recent contract awards

Latest 1 federal contracts awarded to PHOENIX TECHNOLOGIES LLC

Date	Agency	NAICS	Set-aside	Amount
2017-07-28	General Services Administration	611420	NONE	-

Active RFPs in PHOENIX TECHNOLOGIES LLC's primary NAICS (611420)

Open opportunities matching this vendor's NAICS specialty

Track vendors like PHOENIX TECHNOLOGIES LLC on BidSparq

See incumbent vendors on every RFP. Search 19K+ SAM-registered contractors. Find teaming partners by NAICS, state, and certification. AI-scored matches against your business profile.

Start free trial →